Clara Natoli

List of Publications by Year
in descending order

161 papers	4,824 citations	117625 34 h-index	138484 58 g-index
164 all docs	164 docs citations	164 times ranked	6740 citing authors

#	Article	IF	Citations
1	Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?. Trends in Immunology, 2002, 23, 313-320.	6.8	493
2	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. , 2019, 7, 57.		275
3	Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. International Journal of Cancer, 2000, 85, 545-554.	5.1	194
4	90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconjugate Journal, 2002, 19, 551-556.	2.7	148
5	PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. Oncotarget, 2016, 7, 19738-19747.	1.8	134
6	Galectinâ€3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis. FEBS Letters, 2000, 473, 311-315.	2.8	131
7	Prognostic value of a novel circulating serum 90K antigen in breast cancer. British Journal of Cancer, 1994, 69, 172-176.	6.4	123
8	Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Breast, 2019, 44, 33-38.	2.2	109
9	Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to Î±-interferon therapy in chronic HCV hepatitis patients. Journal of Hepatology, 1996, 25, 212-217.	3.7	88
10	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. European Journal of Cancer, 2020, 128, 17-26.	2.8	85
11	Triple positive breast cancer: A distinct subtype?. Cancer Treatment Reviews, 2015, 41, 69-76.	7.7	83
12	GYNÃ†COMASTIA WITH CIMETIDINE. Lancet, The, 1977, 309, 1319.	13.7	80
13	Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. Expert Review of Vaccines, 2016, 15, 1327-1336.	4.4	79
14	Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations. British Journal of Cancer, 2019, 120, 57-62.	6.4	68
15	LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis. Journal of Molecular Medicine, 2013, 91, 83-94.	3.9	63
16	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 474-485.	10.7	59
17	What links BRAF to the heart function? new insights from the cardiotoxicity of BRAF inhibitors in cancer treatment. Oncotarget, 2015, 6, 35589-35601.	1.8	57
18	A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. Oncotarget, 2017, 8, 56921-56931.	1.8	53

#	Article	IF	Citations
19	Hormone-modulated rRNA gene activity is visualized by selective staining of the NOs. Cell Biology International Reports, 1985, 9, 791-796.	0.6	52
20	Measurement of a breast cancer associated antigen detected by monoclonal antibody SP-2 in sera of cancer patients. Breast Cancer Research and Treatment, 1988, 11, 19-30.	2.5	52
21	Purification and characterization of a 90 kDa protein released from human tumors and tumor cell lines. FEBS Letters, 1993, 319, 59-65.	2.8	46
22	Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Letters, 2008, 270, 229-233.	7.2	44
23	Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis. Anticancer Research, 2009, 29, 403-10.	1.1	43
24	Lack of Expression of Galectin-3 Is Associated With a Poor Outcome in Node-Negative Patients With Laryngeal Squamous-Cell Carcinoma. Journal of Clinical Oncology, 2002, 20, 3850-3856.	1.6	42
25	Two new estrogen-supersensitive variants of the MCF-7 human breast cancer cell line. Breast Cancer Research and Treatment, 1983, 3, 23-32.	2.5	40
26	90K (Mac-2 BP) in human milk. Clinical and Experimental Immunology, 1996, 104, 543-546.	2.6	40
27	Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. Blood, 2000, 96, 3282-3285.	1.4	39
28	Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study. Breast Cancer Research and Treatment, 2014, 147, 599-607.	2.5	39
29	Risk factors for locoregional disease recurrence after breastâ€conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient metaâ€analysis. Cancer, 2018, 124, 2923-2930.	4.1	39
30	Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells. Journal of Experimental and Clinical Cancer Research, 2018, 37, 236.	8.6	38
31	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study. Immunotherapy, 2018, 10, 1229-1239.	2.0	38
32	Tyrosine Kinase Inhibitors. Current Cancer Drug Targets, 2010, 10, 462-483.	1.6	37
33	Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies. Cancers, 2013, 5, 919-942.	3.7	37
34	Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094237.	3.2	37
35	Recombinant human leukocyte interferon-Î± 2b stimulates the synthesis and release of a 90k tumor-associated antigen in human breast cancer cells. International Journal of Cancer, 1988, 42, 182-184.	5.1	36
36	High expression of 90K (Macâ€2 BP) is associated with poor survival in nodeâ€negative breast cancer patients not receiving adjuvant systemic therapies. International Journal of Cancer, 2009, 124, 333-338.	5.1	36

#	Article	IF	Citations
37	Human milk 90K (Mac-2â€ƒBP): possible protective effects against acute respiratory infections. Clinical and Experimental Immunology, 1999, 115, 91-94.	2.6	35
38	The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. Oncotarget, 2014, 5, 9619-9625.	1.8	35
39	Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer. , 1996, 68, 34-38.		34
40	DNA and S-phase fraction analysis by flow cytometry in prostate cancer. Clinicopathologic implications. Cancer, 1993, 71, 1289-1296.	4.1	33
41	Neoadjuvant chemotherapy in tripleâ€negative breast cancer: A multicentric retrospective observational study in realâ€life setting. Journal of Cellular Physiology, 2018, 233, 2313-2323.	4.1	33
42	â€œTriple positiveâ€•early breast cancer: an observational multicenter retrospective analysis of outcome. Oncotarget, 2016, 7, 17932-17944.	1.8	33
43	Interleukin-30 Promotes Breast Cancer Growth and Progression. Cancer Research, 2016, 76, 6218-6229.	0.9	32
44	Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation. Journal of Oncology, 2019, 2019, 1-13.	1.3	32
45	Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. Journal of Experimental and Clinical Cancer Research, 2020, 39, 279.	8.6	32
46	A 90-kDa Protein Serum Marker for the Prediction of Progression to AIDS in a Cohort of HIV-1+Homosexual Men. AIDS Research and Human Retroviruses, 1993, 9, 811-816.	1.1	31
47	The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?. Critical Reviews in Oncology/Hematology, 2016, 107, 20-32.	4.4	31
48	Glucocorticoids inhibit the stimulatory effect of epidermal growth factor on the initiation of DNA synthesis. Journal of Cellular Physiology, 1981, 107, 155-163.	4.1	30
49	Unusually High Level of a Tumor-Associated Antigen in the Serum of Human Immunodeficiency Virus-Seropositive Individuals. Journal of Infectious Diseases, 1991, 164, 616-617.	4.0	30
50	Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2009, 1795, 62-81.	7.4	30
51	Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer. Journal of Cancer Research and Clinical Oncology, 2012, 138, 221-229.	2.5	30
52	Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment. OncoImmunology, 2016, 5, e1160187.	4.6	30
53	A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study. Cancer Biology and Therapy, 2019, 20, 192-200.	3.4	30
54	Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Oncotarget, 2015, 6, 31604-31612.	1.8	30

#	Article	IF	Citations
55	90K (Mac-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells. , 1998, 79, 23-26.		29
56	Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival. Journal of Pathology, 2002, 197, 218-223.	4.5	29
57	An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase Inhibitors. Current Cancer Drug Targets, 2012, 12, 439-452.	1.6	29
58	Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an ItalianÂSurvey. Clinical Breast Cancer, 2015, 15, e131-e137.	2.4	27
59	Estrogen binding by neoplastic human thymus cytosol. European Journal of Cancer, 1980, 16, 951-955.	0.9	26
60	Lipoprotein 90K in Human Immunodeficiency Virus-Infected Patients: A Further Serologic Marker of Progression. Journal of Infectious Diseases, 1991, 164, 819-819.	4.0	26
61	The Immune Stimulatory Protein 90K Increases Major Histocompatibility Complex Class I Expression in a Human Breast Cancer Cell Line. Biochemical and Biophysical Research Communications, 1996, 225, 617-620.	2.1	26
62	Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. British Journal of Cancer, 1993, 67, 564-567.	6.4	25
63	Changes of Topoisomerase IIÎ± Expression in Breast Tumors after Neoadjuvant Chemotherapy Predicts Relapse-Free Survival. Clinical Cancer Research, 2006, 12, 1501-1506.	7.0	24
64	Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy. Journal of Experimental and Clinical Cancer Research, 2016, 35, 62.	8.6	24
65	Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter â€œreal lifeâ€•study. BMC Cancer, 2017, 17, 753.	2.6	24
66	Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study. Journal of Cancer, 2019, 10, 5926-5934.	2.5	24
67	â€œBack to a false normalityâ€• new intriguing mechanisms of resistance to PARP inhibitors. Oncotarget, 2017, 8, 23891-23904.	1.8	24
68	Effects of type-I and -II interferons on 90K antigen expression in ovarian carcinoma cells. International Journal of Cancer, 1994, 59, 808-813.	5.1	23
69	Unknown primary tumors. Biochimica Et Biophysica Acta: Reviews on Cancer, 2011, 1816, 13-24.	7.4	23
70	Tumor-derived microvesicles: The metastasomes. Medical Hypotheses, 2013, 80, 75-82.	1.5	21
71	Inhibition of Tumor Growth and Angiogenesis by SP-2, an Antiâ€“Lectin, Galactoside-Binding Soluble 3 Binding Protein (LGALS3BP) Antibody. Molecular Cancer Therapeutics, 2014, 13, 916-925.	4.1	21
72	Palbociclib plus endocrine therapy in HER2 negative, hormonal receptorâ€positive, advanced breast cancer: A realâ€world experience. Journal of Cellular Physiology, 2019, 234, 7708-7717.	4.1	21

#	Article	IF	Citations
73	Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. British Journal of Haematology, 1993, 85, 207-209.	2.5	20
74	Differential effect on TCR:CD3 stimulation of a 90-kD glycoprotein (gp90/Mac-2BP), a member of the scavenger receptor cysteine-rich domain protein family. Clinical and Experimental Immunology, 1998, 113, 394-400.	2.6	20
75	Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. Journal of Cancer Research and Clinical Oncology, 2013, 139, 269-280.	2.5	19
76	Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts. OncoTargets and Therapy, 2017, Volume 10, 3007-3015.	2.0	19
77	Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Realâ€world evidence. Journal of Cellular Physiology, 2020, 235, 7900-7910.	4.1	19
78	Triplet Chemotherapy in Patients With Metastatic Colorectal Cancer: Toward the Best Way to Safely Administer a Highly Active Regimen in Clinical Practice. Clinical Colorectal Cancer, 2012, 11, 229-237.	2.3	18
79	Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients. Journal of Thrombosis and Thrombolysis, 2019, 48, 125-133.	2.1	18
80	Treatment of Metastatic Colorectal Cancer Patients â‰¥75 Years Old in Clinical Practice: A Multicenter Analysis. PLoS ONE, 2016, 11, e0157751.	2.5	17
81	The 90K Tumor-Associated Antigen and Clinical Progression in Human Immunodeficiency Virus Infection. Journal of Acquired Immune Deficiency Syndromes, 1995, 10, 450-456.	0.3	16
82	Expression of the 90K Tumor-Associated Protein in Benign and Malignant Melanocytic Lesions. Journal of Investigative Dermatology, 2002, 119, 187-190.	0.7	16
83	Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience. Breast, 2016, 29, 96-101.	2.2	16
84	Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study. Scientific Reports, 2017, 7, 10597.	3.3	16
85	A Realâ€World Multicentre Retrospective Study of Paclitaxelâ€Bevacizumab and Maintenance Therapy as Firstâ€Line for HER2â€Negative Metastatic Breast Cancer. Journal of Cellular Physiology, 2017, 232, 1571-1578.	4.1	16
86	Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios. Journal of Cancer, 2019, 10, 5903-5914.	2.5	16
87	Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma. Oncotarget, 2016, 7, 21259-21271.	1.8	16
88	Tamoxifen induced membrane alterations in human breast cancer cells. The Journal of Steroid Biochemistry, 1984, 20, 425-428.	1.1	15
89	Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study. Immunotherapy, 2018, 10, 643-655.	2.0	15
90	Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting. Cells, 2021, 10, 1685.	4.1	15

#	Article	IF	Citations
91	90K IS A SERUM MARKER OF POOR-PROGNOSIS IN NON-HODGKINS-LYMPHOMA PATIENTS. Oncology Reports, 1994, 1, 723-5.	2.6	15
92	Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon. Digestive Diseases and Sciences, 1999, 44, 1013-1019.	2.3	14
93	Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. Oncotarget, 2015, 6, 42773-42780.	1.8	14
94	Tumor-associated antigen 90K activates myelomonocytic cell line THP-1. Cancer Letters, 1996, 107, 143-148.	7.2	13
95	Estrogen stimulates cell proliferation and the increase of a 52,000 dalton glycoprotein in human breast cancer cells. The Journal of Steroid Biochemistry, 1984, 20, 747-752.	1.1	12
96	A Phase I Study of Recombinant Interferon-Î± Administered as a Seven-Day Continuous Venous Infusion at Circadian-Rhythm Modulated Rate in Patients with Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1995, 18, 27-31.	1.3	12
97	A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. Annals of Oncology, 2007, 18, 1015-1020.	1.2	12
98	Neoadjuvant Sequential Docetaxel Followed by Highâ€Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial. Journal of Cellular Physiology, 2016, 231, 2541-2547.	4.1	12
99	Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin. Journal of Cellular Physiology, 2016, 231, 986-991.	4.1	12
100	Long-term outcome of breast cancer patients with pathologic N3a lymph node stage. Breast, 2017, 32, 79-86.	2.2	12
101	Body mass index modifies the relationship between Î³-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer. BMC Cancer, 2017, 17, 101.	2.6	12
102	Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab. Cancer Biology and Therapy, 2018, 19, 328-334.	3.4	12
103	Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting. Oncotarget, 2017, 8, 69025-69037.	1.8	12
104	Effectiveness and response predictive factors of erlotinib in a non-small cell lung cancer unselected European population previously treated: A retrospective, observational, multicentric study. Journal of Oncology Pharmacy Practice, 2013, 19, 246-253.	0.9	11
105	Long-Term Outcome of Neoadjuvant Endocrine Therapy with Aromatase Inhibitors in Elderly Women with Hormone Receptor-Positive Breast Cancer. Annals of Surgical Oncology, 2014, 21, 1575-1582.	1.5	11
106	Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction. Clinical Genitourinary Cancer, 2017, 15, 520-525.	1.9	11
107	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. Cancer Immunology, Immunotherapy, 2022, 71, 865-874.	4.2	11
108	Expression of tumor-associated 90k-antigen in human breast cancer: No correlation with prognosis and response to first-line therapy with tamoxifen. International Journal of Cancer, 1995, 64, 130-134.	5.1	10

#	Article	IF	Citations
109	Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. Oncotarget, 2017, 8, 54528-54536.	1.8	10
110	Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. International Journal of Cancer, 2000, 85, 545.	5.1	10
111	Cyclooxygenase-independent induction of p21WAF-1/cip1, apoptosis and differentiation by L-745,337, a selective PGH synthase-2 inhibitor, and salicylate in HT-29 cells. Apoptosis: an International Journal on Programmed Cell Death, 1999, 4, 151-162.	4.9	9
112	Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2365-2373.	2.5	9
113	The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status. Oncotarget, 2016, 7, 35803-35812.	1.8	9
114	Palliative radiotherapy in advanced cancer patients treated with immuneâ€'checkpoint inhibitors: The PRACTICE study. Biomedical Reports, 2020, 12, 59-67.	2.0	9
115	Recombinant alpha-2b-interferon enhances the circulating levels of a 90-kilodalton (K) tumor-associated antigen in patients with gynecologic and breast malignancies. Cancer, 1990, 65, 1325-1328.	4.1	8
116	Prognostic Value of a Novel Interferon-inducible 90K Tumor Antigen. Annals of the New York Academy of Sciences, 1996, 784, 288-293.	3.8	8
117	Elevated levels of circulating immunostimulatory 90K in Henoch-Schoenlein purpura. Journal of Clinical Immunology, 1999, 19, 143-147.	3.8	8
118	Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1229-1240.	2.5	8
119	Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review. Journal of Experimental and Clinical Cancer Research, 2013, 32, 89.	8.6	8
120	Breast Cancer â€œTailored Follow-upâ€•in Italian Oncology Units: A Web-Based Survey. PLoS ONE, 2014, 9, e94063.	2.5	8
121	Adherence to hormonal deprivation therapy in prostate cancer in clinical practice: a retrospective, single-center study. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 181-184.	3.9	8
122	Lack of mother-to-child HIV-1 transmission is associated with elevated serum levels of 90 K immune modulatory protein. Aids, 2000, 14, F41-F45.	2.2	7
123	Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?. Cancer Biology and Therapy, 2015, 16, 1704-1709.	3.4	7
124	Rivaroxaban for Cancer-associated Cardiac Thrombosis. American Journal of Medicine, 2015, 128, e43-e44.	1.5	7
125	Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study. Minerva Urology and Nephrology, 2021, 73, 489-497.	2.5	7
126	Relationship between the tumour-associated antigen 90K and cytokines in the circulation of persons infected with human immunodeficiency virus. Journal of Infection, 1994, 28, 31-39.	3.3	6

#	Article	IF	Citations
127	Circulating Autoantibodies to LGALS3BP: A Novel Biomarker for Cancer. Disease Markers, 2013, 35, 747-752.	1.3	6
128	Multicentric retrospective analysis of platinumâ€pemetrexed regimens as firstâ€line therapy in nonâ€squamous nonâ€small cell lung cancer patients: A â€œsnapshotâ€•from clinical practice. Thoracic Cancer, 2018, 9, 241-252.	1.9	6
129	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110598.	3.2	6
130	Growth promoting influences of estradiol, epidermal growth factor, and insulin on human breast cancer: Evidence for differential mechanism of action on tumor cells in vitro. Breast Cancer Research and Treatment, 1985, 6, 255-256.	2.5	5
131	Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer. British Journal of Cancer, 1992, 66, 981-983.	6.4	5
132	Effect of Targeted Agents on the Endocrine Response of Breast Cancer in the Neoadjuvant Setting: A Systematic Review. Journal of Cancer, 2015, 6, 575-582.	2.5	5
133	Predictive Ability for Disease-Free Survival of the GRade, Age, Nodes, and Tumor (GRANT) Score in Patients with Resected Renal Cell Carcinoma. Current Urology, 2020, 14, 98-104.	0.6	5
134	A multidisciplinary group for prostate cancer management: A single institution experience. Oncology Letters, 2017, 15, 1823-1828.	1.8	4
135	A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression. Case Reports in Oncological Medicine, 2019, 2019, 1-4.	0.3	4
136	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel antiâ€HER2 agents in the real world setting. International Journal of Cancer, 2020, 146, 1917-1929.	5.1	4
137	Cyclooxygenase-Independent Induction of P2LWAF-1/CIP1, Apoptosis and Differentiation by L-745, 337 and Salicylate in HT-29 Colon Cancer Cells. Advances in Experimental Medicine and Biology, 1999, 469, 555-561.	1.6	4
138	Relationship and Predictive Role of the Dual Expression of FGFR and IL-8 in Metastatic Renal Cell Carcinoma Treated with Targeted Agents. Anticancer Research, 2018, 38, 3105-3110.	1.1	4
139	Growth inhibitory effects of thyroid hormones on androgen-dependent mammary tumor cells. The Journal of Steroid Biochemistry, 1981, 15, 409-413.	1.1	3
140	Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study. British Journal of Cancer, 2004, 91, 618-620.	6.4	3
141	DNA ploidy and S-phase fraction in pulmonary carcinoids. European Journal of Cancer, 1992, 28, 1933-1934.	2.8	2
142	Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer. Journal of Human Genetics, 2017, 62, 379-387.	2.3	2
143	Extraordinary and prolonged Erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report. International Medical Case Reports Journal, 2017, Volume 10, 173-175.	0.8	2
144	Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591985319.	3.2	2

#	Article	IF	Citations
145	Tgf-Î²1 transcriptionally promotes 90K expression: possible implications for cancer progression. Cell Death Discovery, 2021, 7, 86.	4.7	2
146	Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. Blood, 2000, 96, 3282-3285.	1.4	2
147	Effect of thyroid hormones on androgen responsiveness in a mammary tumor cell line. The Journal of Steroid Biochemistry, 1981, 15, 415-419.	1.1	1
148	Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib . International Medical Case Reports Journal, 2020, Volume 13, 89-93.	0.8	1
149	Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study. Tumori, 2014, 100, e309-13.	1.1	1
150	Combinations of biological response modiifiers: rationale and clinical responses.. Pharmacological Research, 1992, 26, 102-103.	7.1	0
151	Chemotherapy-Induced Nausea and Vomiting in Italian Cancer Centers: Results of CINVDAY, a Prospective, Multicenter Study. Tumori, 2014, 100, e309-e313.	1.1	0
152	Impact of Body Mass Index (BMI) on outcome of metastatic breast cancer (MBC) patients (pts) treated with Eribulin in a real-world population: a multicenter retrospective study. Annals of Oncology, 2015, 26, vi13.	1.2	0
153	Reply to Kadri Altundag: Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage?. Breast, 2017, 35, 218-219.	2.2	0
154	NAB-Paclitaxel (NAB-P) in HER2-ve Advanced Breast Cancer (ABC) Patients (PTS): Focus on Luminal Cancers. Results from GIM13-AMBRA Study. Breast, 2017, 36, S51-S52.	2.2	0
155	Is There Still a Role for Endocrine Therapy Alone in HR+/HER2â€“ Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. Breast Care, 2020, 15, 30-37.	1.4	0
156	New Targets for Therapy in Pancreatic Cancer. , 0, , .		0
157	Treatment (T) of metastatic colorectal cancer (mCRC) patients (pts) â‰¥75 years (y) old in clinical practice: A multicenter analysis.. Journal of Clinical Oncology, 2014, 32, e14514-e14514.	1.6	0
158	Abstract 2684: Inhibition of tumor growth and angiogenesis by SP-2, an anti-LGALS3BP antibody. , 2014, , .		0
159	Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A restrospective multicenter observational study.. Journal of Clinical Oncology, 2015, 33, e11542-e11542.	1.6	0
160	CARAMEL study: Clinical prognostic biomarkers for ipilimumab-related outcome in metastatic melanoma patients.. Journal of Clinical Oncology, 2016, 34, e21009-e21009.	1.6	0
161	Long-term outcome of pemetrexed maintenance for advanced nonsquamous non-small-cell lung cancer: a real-world observational cohort study. Recenti Progressi in Medicina, 2020, 111, 761-768.	0.8	0